Kornimate/medical-research-clean huggingface dataset:
the androtriol injection for the treatment of acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: this is a prospective, multicenter, randomized, double-blind, placebo-controlled, phase iib clinical trial of androtriol injection for the treatment of acute ischemic stroke. the goal of this trial is to explore the efficacy and safety of different doses of androtriol injection in patients with acute ischemic stroke (ais) who received vascular recanalization treatment within 24 hours of symptom onset. participants will receive a low-dose androtriol injection (100 mg bid), a high-dose androtriol injection (300 mg bid), or a placebo intravenously within 24 hours of stroke onset. they will be treated twice daily (every 12 hours) for 7 days, with a total of 14 doses over the course of the study. each infusion will last approximately 30±5 minutes.


Eligibility criteria:
inclusion criteria: 1. age 18- 80 years, male or female； 2. mrs score ≤1 prior to this onset; 3. planning to receive or have received intravascular recanalization therapy at our center within 24h of onset; 4. to complete the first administration of the investigational medication within 24h of onset; 5. nihss（national institutes of health stroke scale）score≥6 prior to intravascular recanalization; 6. informed consent. exclusion criteria: 1. intracranial hemorrhagic diseases, including hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc.; 2. severe disorders of consciousness: nihss 1a≥2 points; 3. large infarct core (aspects \ 1/3 of mca territory involved, as evidenced by ct or mri); 4. severe hypertension: systolic blood pressure ≥185mmhg or diastolic blood pressure ≥110mmhg after medication control; 5. history of severe kidney disease (such as dialysis), or egfr \<45 ml/min/1.73m²; 6. history of severe liver disease, or alt, ast levels more than 3 times of the upper limit of normal, or bilirubin more than 3 times of the upper limit of normal; 7. cardiovascular diseases, such as complete atrioventricular block, history of congestive heart failure (chf), or heart function classification≥nyha class iii; 8. critically ill patients with an expected lifespan≤90 days; 9. history of epilepsy or epilepsy-like symptoms during stroke or severe psychiatric disorders, intellectual disability, or dementia; 10. history of intracranial hemorrhage; 11. severe injury or surgery history within 3 months of onset; 12. have received\>1 dose of neuroprotective drugs after this onset, such as edaravone, edaravone dexborneol injection, ginkgo lactone, ginkgo diterpene glucamine，etc; 13. allergy to the investigational drug (either the active ingredient androtriol or the excipient hydroxypropyl beta-cyclodextrin) or similar chemical structure drugs; 14. pregnant or breastfeeding; 15. participation in other clinical trials within 3 months of onset; 16. unsuitable for participating in this study judged by investigator.

Keywords: androtriol acute ischemic stroke
effect of the duration of preoperative fasting on hypotension induced by general anesthesia in the elderly person

Conditions: Preoperative Fasting and Hypotension

Summary: this study aims to determine if prolonged fasting represents an independent risk factor for hypotension during induction of general anesthesia in the elderly.

preoperative fasting aims to reduce the risk of adverse events (eg, inhalation), but may be responsible for dehydration whose consequence is a major hypotension. this problem of hypotension is important because it (map \<55 mmhg) is directly correlated to the occurrence of pejorative events on the cardiac and renal level and even more so that the duration of the hypotension is long.

Eligibility criteria:
inclusion criteria: * risk score anesthetic asa i-iii * patients ≥ 70 years * suffering from a femoral neck fracture to be treated surgically: * either through prosthesis, * either by intramedullary nailing (gamma nail) exclusion criteria: * risk score anesthetic asa iv * patient on angiotensin converting enzyme (ace) inhibitors or arbs (ara2) within 10 hours before surgery * obesity (bmi\> 35) or weight \<40kg * need to make a rapid sequence induction * inability to achieve the femoral block (standardization of induction) or patient refusal with respect to the technique.
therapeutic efficacy of quercetin versus its encapsulated nanoparticle on tongue squamous cell carcinoma cell line

Conditions: Oral Cancer

Summary: squamous cell carcinoma (scc) is the most common oral cavity carcinoma. conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations.the major obstacle of using current anticancer drugs is; first the non-specific tissue distribution, as these drugs are unable to distinguish between normal and cancer cells.quercetin is a bioactive flavonoid having strong antioxidant properties. .among all the nanomaterials, polymeric nanoparticles are of significant interest for drug delivery applications due to many unique features of nanoparticle polymers.this is the first study to investigate the anticancer effects of (quercetin) either free or encapsulated by plga-peg nps in tongue squamous cell carcinoma (tscc) cell line.

squamous cell carcinoma (scc) is the most common oral cavity carcinoma. conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations. the major obstacle of using current anticancer drugs is; first the non-specific tissue distribution, as these drugs are unable to distinguish between normal and cancer cells. quercetin is a bioactive flavonoid having strong antioxidant properties. it is naturally present in a wide variety of fruits and vegetables. among all the nanomaterials, polymeric nanoparticles are of significant interest for drug delivery applications due to many unique features of nanoparticle polymers. polymeric nanocarriers have been fabricated from natural and synthetic polymers. poly ethylene glycol-poly lactide-co-glycolic acid (peg-plga) amphiphilic copolymer is an emergent system because it can be easily synthesized and possesses a lot of good qualities. several previous in vitro and in vivo studies have evaluated the cytotoxic effects of quercetin and have revealed that it decreases cell viability and increases cell apoptotic rate in oscc. however, the anti-cancer property of quercetin in tongue squamous cell carcinoma (tscc) has not been studied yet. this is the first study to investigate the anticancer effects of (quercetin) either free or encapsulated by plga-peg nps in tongue squamous cell carcinoma (tscc) cell line.

Eligibility criteria:
inclusion criteria: * tongue squamous cell carcinoma cell lines * quercetin drug. * quercetin-encapsulated plga-peg nanoparticles (nano-qut) * application of a quercetin drug as chemotherapeutic drug. * detection of quercetin activity in apoptosis or cytotoxicity/cell viability. exclusion criteria: * any cancer cell line other than tongue squamous cell carcinoma cell lines * any use of quercetin other than chemotherapy. * detection of quercetin activities other than apoptosis or cytotoxicity/cell viability

Keywords: tongue scc chemotherapy quercetin plga-peg nanoparticle
correlation of pelvic asymmetry and joint movement during gait in children with cerebral palsy

Conditions: Correlation of Pelvic Asymmetry and Joint Movement During Gait in Children With Cerebral Palsy

Summary: the study's particular goals were to determine whether excessive hip, knee, and ankle displacement at first contact during locomotion correlates with pelvic rotation.


Eligibility criteria:
inclusion criteria: * the lower extremities' degree of spasticity ranged from grade 1 to grade +1 on the gross motor function classification system (gmfcs) \[7\] classified motor function levels as being between levels i and ii. children have the cognitive ability to understand and follow instructions. exclusion criteria: * having an extensive intellectual disability, orthopedic issues, upper or lower limb surgery, visual or hearing issues, usage of behavior-altering medicines, or a major neurological illness (epilepsy)

Keywords: cerebral palsy pelvic obliquity joint movement
crux biomedical evaluation of the crux inferior vena cava filter system 3 ("retrieve 3")

Conditions: Pulmonary Embolism

Summary: the purpose of this study is to determine if the crux vena cava filter system is safe and effective in preventing pulmonary embolism.


Eligibility criteria:
inclusion criteria: * patient has a permanent or temporary risk of pulmonary embolism. * patient must provide informed consent at least one of the following conditions - * proven pe * recurrent pe despite adequate * contraindication to anticoagulation * inability to achieve/maintain therapeutic anticoagulation * iliocaval dvt * large, free-floating proximal dvt * massive pe treated with thrombolysis/thrombectomy * chronic pe treated with thrombectomy * protection during thrombolysis for iliocaval dvt * pe with limited cardiopulmonary reserve * poor compliance with anticoagulation medication * high risk of injury worsening on anticoagulation * multi-trauma patient with high risk of pe * surgical patients at high risk of pe * medical condition with high risk of pe patients with a documented vena cava diameter of 17-28mm patient has ivc anatomy suitable for infra-renal placement patient is willing to be available for the appropriate follow up exclusion criteria: * age \<18 years old * patient has any one of the following conditions: * renal vein thrombosis * ivc thrombosis extending to the renal veins * duplicate ivc * gonadal vein thrombosis * requires supra-renal placement * vena cava diameter of 17-28mm * uncontrolled infectious disease * risk of aseptic pe * uncontrolled coagulopathy * existing inferior vena cava filter implant * life expectancy less than 6 months * pregnant or planning a pregnancy in the next 6 months * condition that inhibits radiographic visualization of the ivc * known allergy or intolerance to polytetrafluoroethylene (ptfe) or nitinol * known hypersensitivity to contract which cannot be pretreated * access vessels preclude same insertion of delivery system * participation in another drug or device trial * unable or unwilling to cooperate with study procedures or required follow-up visits

Keywords: vena cava vena cava filter pulmonary embolism venous thromboembolism risk of pulmonary embolism
pioglitazone vs vitamin e vs placebo for treatment of non-diabetic patients with nonalcoholic steatohepatitis (pivens)

Conditions: Liver Diseases

Summary: the purpose of this study is to determine if therapy with pioglitazone or vitamin e will lead to an improvement in liver histology in non-diabetic adult patients with non-alcoholic steatohepatitis (nash).

the purpose of this study is to determine if therapy with pioglitazone or vitamin e will lead to an improvement in liver histology in non-diabetic adult patients with non-alcoholic steatohepatitis (nash).

Eligibility criteria:
* histologic evidence of nash based on a liver biopsy obtained within 6 months of randomization. * age 18 years or older

Keywords: non alcoholic steatohepatitis steatohepatitis
reviparin-bridging-in a general practice setting in germany

Conditions: Thromboembolism

Summary: in view of the fact that little is known about the pre- and post-interventional coagulation management of phenprocoumon patients with reviparin at general practices in germany, an observational study is being initiated to evaluate the effectiveness and tolerability of reviparin in the area of outpatient, general practice-based care in the context of bridging therapy. patients for whom bridging therapy with low-molecular weight heparin (lmwh) was specified and for whom the lmwh reviparin was chosen for this purpose shall be investigated.


Eligibility criteria:
inclusion criteria: * patients \> 18 years old * requiring prophylaxis/bridging treatment with reviparin, e.g. for the prevention of venous thromboembolism in general and orthopaedic surgery, due to the decision of the treating physician exclusion criteria: * hypersensitivity to reviparin or one of the excipients of clivarin® or other low-molecular-weight heparin preparations and/or heparin, e.g. confirmed or suspected immune-mediated heparin-induced thrombocytopenia (type 2) * severe renal impairment (creatinine clearance \< 30 ml/min) * bleeding: like other anticoagulants, reviparin should not be used in conditions associated with an increased risk of bleeding, e.g. acute bleeding, haemorrhagic diathesis, coagulation factor deficiencies, severe thrombocytopenia, untreated arterial hypertension, bacterial endocarditis and subacute endocarditis, acute-onset gastrointestinal ulcers or haemorrhages, brain haemorrhage, spinal or ear or eye surgery, intraocular bleeding or corresponding injuries within the past 6 months * severe hepatic or pancreatic impairment * children * patients with a body weight \< 45kg * life expectancy of less than 3 months * pregnant women (due to the generally very long duration of treatment with lmwh in female patients who are already on anticoagulation therapy)

Keywords: reviparin bridging phenprocoumon
thalidomide/dexamethasone treatment and pet evaluation in organ involvemenet of cardiac amyloidosis

Conditions: Cardiac Amyloidosis

Summary: to prove the organ-reversing potential of thalidomide for amyloidosis with cardiac involvement

considering that dismal prognosis of amyloidosis is attributable to organ dysfunction, primary aim of amyloidosis treatment should be an organ reversal. however, due to various reasons, not much is known about organ reversal in amyloidosis. almost all of the clinical trials evaluated hematologic response in amyloidosis. meanwhile, besides autologous stem cell transplantation with high-dose melphalan conditioning, hematologic response rate of various agents such as bortezomib, melphalan, thalidomide and lenalidomide are similar for amyloidosis. however, organ reversing potential of these agents is not known. if there is a difference in organ reversing potential despite of similar hematologic response rate, drug with effective organ reversing potential should be a standard treatment for amyloidosis. the investigators assume that thalidomide could make organ reversal in cardiac amyloidosis due to its specific mechanism of action. to prove this concept, the investigators propose a clinical trial that evaluates organ reversing potential of thalidomide in cardiac amyloidosis.

Eligibility criteria:
inclusion criteria: 1. age : more than 18 years old 2. cardiac amyloidosis (both al or ah type) patient who meet both (a and b) of the following criteria a. cardiac involvement: meet one of the following criteria * echocardiography: mean wall thickness \>12 mm, and no other cardiac cause * ntprobnp \>332 ng/l in the absence of renal failure * evidence of cardiac amyloidosis in cardiac mri b. treatment history: no history of exposure to thalidomide 3. ecog(eastern cooperative oncology group) performance status ≤ 3 4. tolerable major organ function determined by laboratory examination i. serum creatinine ≤ 3.0 mg/dl ii. absolute neutrophil count ≥ 1000/μl iii. platelet ≥ 75000/ μl iv. hemoglobin ≥ 8.0 mg/dl v. bilirubin \< 2 times or alkaline phosphate \< 4 times upper limit of normal 5. expected survival \> 3 months 6. female participants of child-bearing potential must have a negative pregnancy test prior to treatment and agree to use dual methods of contraception for the duration of the study and for 30 days following completion of study. male participants must also agree to use a barrier method of contraception for the duration of the study and for 30 days following completion of study if sexually active with a female of child-bearing potential. exclusion criteria: 1. amyloidosis without cardiac involvement 2. patients who are planning to receive autologous stem cell transplantation 3. patients who received autologous stem cell transplantation, remained in hematologic complete response 4. pregnant, lactating or unwilling to use adequate contraception 5. systemic infection unless specific anti-infective therapy is employed 6. known allergies to thalidomide 7. previous experimental agents or approved anti-tumor treatment within 1 months before the date of registration

Keywords: thalidoide
study comparing the bioavailability of tas-102 tablets to an oral solution containing equivalent amounts of ftd and tpi

Conditions: Advanced Solid Tumors (Excluding Breast Cancer)

Summary: the purpose of this study is to compare the bioavailability of tas-102 tablets to an oral solution containing equivalent amounts ftd and tpi.

this is a phase 1, open-label, randomized, 2-sequence, 3-period crossover study evaluating the relative bioavailability of tas-102 tablets compared to an oral solution in patients with advanced solid tumors. this study will be conducted in 2 parts. the crossover bioavailability part will be followed by an extension conducted with tas-102 tablets only.

Eligibility criteria:
inclusion criteria: 1. has provided written informed consent 2. has advanced solid tumors (excluding breast cancer) for which no standard therapy exists 3. ecog performance status of 0 or 1 4. is able to take medications orally 5. has adequate organ function (bone marrow, kidney and liver) 6. women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. males must agree to adequate birth control. exclusion criteria: 1. has had certain other recent treatment e.g. anticancer therapy, received investigational agent, within the specified time frames prior to study drug administration 2. certain serious illnesses or medical condition(s) 3. has had either partial or total gastrectomy 4. has unresolved toxicity of greater than or equal to ctcae grade 2 attributed to any prior therapies 5. known sensitivity to tas-102 or its components 6. is a pregnant or lactating female 7. refuses to use an adequate means of contraception (including male patients)

Keywords: advanced solid tumors (excluding breast cancer) for which no standard therapy exists
olanzapine for acute headaches

Conditions: Headache

Summary: this trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular medications.

primary question: does oral rapidly dissolving olanzapine provide efficacious analgesia in patients with acute headache of non-organic origin (primary headache) who come to the ed for abortive therapy when compared to current standard of care? secondary aim: additionally, the study will aim to see if oral rapidly dissolving olanzapine decreases 1) duration of ed length of stay and 2) need for iv access when compared to the current standard of care. this is a prospective, randomized, convenience sample, feasibility trial to test for non-inferiority of oral rapidly dissolving olanzapine versus current emergency department standard of care in providing symptomatic relief to patients presenting with primary headache.

Eligibility criteria:
inclusion criteria: 1. adult patient between 18-65 years of age presenting to the emergency department with acute primary headache 2. patient approved for inclusion by primary attending physician in the emergency department exclusion criteria: 1. age \ 65 2. pregnancy 3. known allergy to olanzapine 4. known qt prolongation or underlying condition that places patient at risk for qt prolongation 5. inability to give written consent (intoxication, altered mental status) 6. headache of organic origin (trauma, infection, previous recent head or neck surgery) 7. patient already prescribed daily olanzapine on an outpatient basis 8. patient has been administered olanzapine within the past 24 hours 9. language barrier
an evaluation of the long-term safety of magnesium iron hydroxycarbonate

Conditions: Chronic Kidney Failure

Summary: fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. the purpose of this study it to look at the safety of fermagate over longer periods of time.

high levels of phosphate in the blood are linked with serious effects, due to calcium imbalances (high levels of parathyroid hormone (pth), bone disease, formation of calcium deposits in the body, and blood-vessel disease). this study is an open-label, multi-centre, single-group, 24-week study of fermagatebonate. subjects participating in this study are those who took at least one dose of double-blind study medication in the ih 001 study and either completed study ih 001 or were withdrawn due to reasons other than an adverse event (ae) considered related to study treatment.

Eligibility criteria:
inclusion criteria: 1. taken at least one dose of double-blind medication during study ih 001 and either completed study ih 001 or were withdrawn due to reasons other than an ae considered related to study treatment 2. male or female subjects on active haemodialysis, aged 18 years or over 3. willing to abstain from taking any phosphate binder or oral magnesium-, aluminium-, or iron-containing products and preparations, other than the study medication; 4. willing to avoid any intentional changes in diet such as fasting, dieting or overeating; 5. willing to maintain their usual type and dose of vitamin d supplementation. exclusion criteria: 1. participation in any other clinical trial using an investigational product or device within the previous 4 months; 2. a significant history of alcohol, drug or solvent abuse in the opinion of the investigator; 3. any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn; 4. clinically significant laboratory findings (for this subject population) in the opinion of the investigator. 5. any malignancy with the exception of basal cell carcinoma; 6. a history of a motility disorder of the intestines, including, but not limited to, gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction; 7. a significant illness in the 4 weeks before screening; 8. taking medication for seizures; 9. a history of haemochromatosis; 10. a history of serum ferritin concentration of ≥ 1000 ng/ml (excluding transient, treatment-induced ferritin elevation); 11. a history of dysphagia or swallowing disorders; 12. female subjects who are lactating or pregnant. women of childbearing potential (pre-menopausal and not surgically sterilised) unless they abstain from sexual intercourse or are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device; 13. current haemoglobin concentration of \< 10.00 g/dl; 14. allergy to the imp or its constituents.
relation between intrabdominal pressure and collapsibility index of inferior vena cava before and after fluid therapy

Conditions: Abdominal Compartment Syndrome

Summary: this study assess the relation between intra abdominal pressure and collapsibility index of inferior vena cava in emergency bedside ultrasonography before and after fluid therapy.


Eligibility criteria:
inclusion criteria: * body mass index less than 30 * written agree of the patient to participate in the study exclusion criteria: * neurogenic bladder or any documented previous surgery on bladder, spastic or contractile bladder * large abdominal hernia * patients who received neuromuscular blocking agents * patients with abdominal respiration due to chest pain

Keywords: intrabdominal pressure emergency bedside ultrasonography abdominal compartment syndrome